SynthesisRheumatology (Oxford, England)2022
Treatment strategies for Sjögren's syndrome with childhood onset: a systematic review of the literature.
Synthesis in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Guideline
- Managing Sjögren's Disease in Pediatric Patients.Paediatric drugs · 2026Review
- Pediatric Sjögren's Disease: Literature Review and Diagnostic Challenges in an Uncommon Case.Diagnostics (Basel, Switzerland) · 2026Article
- Childhood Sjögren's Disease: A Literature Review of an Underrecognized Autoimmune Entity in Pediatric Rheumatology.Cureus · 2025Review
- Childhood-onset primary Sjögren's Syndrome presenting as nephrotic syndrome: a case report and literature review.BMC pediatrics · 2025Review
- Pediatric Sjögren's Syndrome: Focus on Ocular Involvement and Diagnostic Challenges.Medicina (Kaunas, Lithuania) · 2025Article
- Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Article
- Spectrum of Central Nervous System Involvement in Childhood-Onset Sjögren's Syndrome: A Case-Based Review.Mediterranean journal of rheumatology · 2024Article
- The Florida Scoring System for stratifying children with suspected Sjögren's disease: a cross-sectional machine learning study.The Lancet. Rheumatology · 2024Article
- Kidney manifestations of pediatric Sjögren's syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Juvenile Primary Sjögren Syndrome in a 15-Year-Old Boy with Renal Involvement: A Case Report and Review of the Literature.Diagnostics (Basel, Switzerland) · 2024Article
- Cardiovascular risk and inflammation in a population with autoimmune diseases: a narrative review.Frontiers in immunology · 2024Review
- CD8International journal of molecular sciences · 2022Review
- Pediatric rheumatologists' perspectives on diagnosis, treatment, and outcomes of Sjögren disease in children and adolescents.Pediatric rheumatology online journal · 2022Article
- Multi-Omic Biomarkers for Patient Stratification in Sjogren's Syndrome-A Review of the Literature.Biomedicines · 2022Review
- Evaluation and management of dry mouth and its complications in rheumatology practice.Expert review of clinical immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
objectivesSS with childhood onset is a rare autoimmune disease characterized by heterogeneous presentation. The lack of validated classification criteria makes it challenging to diagnose. Evidence-based guidelines for treatment of juvenile SS are not available due to the rarity of disease and the paucity of research in this patient population. This systematic review aims to summarize and appraise the current literature focused on pharmacological strategies for management of SS with childhood onset.
methodsPubMed and MEDLINE/Scopus databases up to December 2020 were screened for suitable reports highlighting pharmacological treatment of SS with childhood onset using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 reporting checklist. Animal studies were excluded.
resultsA total of 43 studies (34 case reports, 8 mini case series and 1 pilot study) were eligible for analysis. The studies retrieved included girls in 88% (120/137) of cases and had very low confidence levels. HCQ was prescribed for parotid swelling, as well as in association with MTX and NSAIDs in patients with arthritis and arthralgia. Corticosteroids such as long courses of oral prednisone and i.v. methylprednisolone were commonly prescribed for children with severe disease presentations. Rituximab was mainly indicated for mucosa-associated lymphoid tissue lymphoma and renal and nervous system complications. Other conventional DMARDs were prescribed in selected cases with extraglandular manifestations.
conclusionVarious therapies are used for the management of juvenile SS and are prescribed based on expert clinician's opinion. There are currently no good-quality studies that allow clinical recommendations for treatment of SS with childhood onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.